Seniors With Certain Cardiovascular Diseases Saw Life's Essential 8 Scores Decline 2013 to 2018
By Elana Gotkine HealthDay Reporter

WEDNESDAY, Aug. 20, 2025 -- From 2013 to 2018, older adults with heart failure, stroke, and hypertension experienced significant declines in Life's Essential 8 (LE8) scores, according to a study published online Aug. 20 in the Journal of the American Heart Association.
James M. Walker, from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues examined recent trends in LE8 scores among noninstitutionalized older U.S. adults (ages 65 years and older) with prevalent cardiovascular disease (CVD). CVD diagnoses were self-reported; within each diagnosis group, percent change in LE8 scores was calculated from 2013 to 2018.
The 3,050 study participants represented 37,908,305 U.S. adults. The researchers found that between 2013 to 2014 and 2017 to 2018, LE8 scores tended to stay stable or decline for those with and without CVD. In those with hypertension, stroke, and heart failure, significant decreases in mean LE8 scores were seen, with a 4.1, 11.5, and 15.2 percent decline, respectively.
"Physical activity and blood pressure scores tended to be very low for people with cardiovascular disease," Walker said in a statement. "On average, participants with one cardiovascular disease had a Life's Essential 8 score 9 points lower than those without cardiovascular disease. That gap seemed to be explained by low scores for blood pressure and physical activity."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-08-21 06:00
Read more

- Magnetic Stimulation, TTNS Both Beat Bladder Training Alone in Overactive Bladder
- Fighters From Poor Neighborhoods Might Have Higher Brain Risk
- Federal Judge Halts Plan to Defund Planned Parenthood Through Medicaid
- Fast Walking Pace Linked to Reduced Mortality
- ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes
- FDA Picks George Tidmarsh to Head Center for Drug Evaluation and Research
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions